Financials Bonesupport Holding AB

Equities

BONEX

SE0009858152

Pharmaceuticals

Real-time Estimate Cboe Europe 06:31:14 2024-07-04 am EDT 5-day change 1st Jan Change
269.2 SEK +2.28% Intraday chart for Bonesupport Holding AB +0.90% +42.93%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,689 4,945 2,823 5,191 12,243 17,298 - -
Enterprise Value (EV) 1 1,607 4,602 2,638 4,989 12,076 17,036 16,809 16,489
P/E ratio -10.5 x -45.1 x -32.8 x -75.9 x 50.3 x 130 x 64.5 x 36.6 x
Yield - - - - - - 0.39% -
Capitalization / Revenue 10.9 x 27.3 x 13.3 x 15.8 x 20.7 x 20.1 x 14.4 x 11.2 x
EV / Revenue 10.3 x 25.4 x 12.4 x 15.2 x 20.4 x 19.8 x 14 x 10.7 x
EV / EBITDA -10.7 x -46.7 x -32.7 x -77.3 x 867 x 108 x 51.2 x 27.1 x
EV / FCF -9.54 x -44.7 x -30.4 x -99.4 x -633 x 116 x 64.3 x 49.2 x
FCF Yield -10.5% -2.24% -3.29% -1.01% -0.16% 0.86% 1.56% 2.03%
Price to Book 13.6 x 12.4 x 10.6 x 19.3 x 22.6 x 25.6 x 19.2 x -
Nbr of stocks (in thousands) 51,956 63,723 64,162 64,521 65,056 65,721 - -
Reference price 2 32.50 77.60 44.00 80.45 188.2 263.2 263.2 263.2
Announcement Date 2/26/20 2/17/21 2/17/22 2/16/23 2/15/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 155.5 180.9 212.9 328.8 591.1 859 1,200 1,545
EBITDA 1 -150.4 -98.56 -80.67 -64.54 13.93 158.4 328.4 609
EBIT 1 -158.1 -98.56 -80.67 -64.54 13.93 152.3 321 598.5
Operating Margin -101.67% -54.5% -37.89% -19.63% 2.36% 17.73% 26.75% 38.74%
Earnings before Tax (EBT) 1 -158.3 -99 -81.84 -64.69 15.75 152.7 322 597
Net income 1 -161.1 -101.4 -85.53 -68.17 245 133.4 267.6 474
Net margin -103.58% -56.07% -40.18% -20.73% 41.45% 15.53% 22.3% 30.68%
EPS 2 -3.100 -1.720 -1.340 -1.060 3.740 2.020 4.083 7.200
Free Cash Flow 1 -168.5 -102.9 -86.84 -50.19 -19.08 146.8 261.6 335
FCF margin -108.36% -56.91% -40.79% -15.26% -3.23% 17.08% 21.8% 21.69%
FCF Conversion (EBITDA) - - - - - 92.62% 79.67% 55.01%
FCF Conversion (Net income) - - - - - 109.99% 97.75% 70.68%
Dividend per Share 2 - - - - - - 1.020 -
Announcement Date 2/26/20 2/17/21 2/17/22 2/16/23 2/15/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 61.4 66.34 74.6 84.62 103.2 119.7 140.4 158.2 172.7 184.4 200 220.1 246.9 263.2
EBITDA - - - - - - - - - - - - - -
EBIT 1 -21.77 -16.46 -14.9 -13.94 -19.28 0.768 5.952 14.87 -7.658 32.29 38.7 49.2 66.7 80.7
Operating Margin -35.46% -24.8% -19.97% -16.47% -18.68% 0.64% 4.24% 9.4% -4.43% 17.51% 19.35% 22.35% 27.01% 30.66%
Earnings before Tax (EBT) -22.05 -16.67 - - - - - - - - - - - -
Net income -24.2 -16.37 - - - - - - - - - - - -
Net margin -39.42% -24.68% - - - - - - - - - - - -
EPS - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 2/17/22 5/4/22 7/14/22 10/27/22 2/16/23 4/27/23 7/13/23 10/26/23 2/15/24 4/25/24 - - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 81.7 343 185 201 167 262 489 809
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -168 -103 -86.8 -50.2 -19.1 147 262 335
ROE (net income / shareholders' equity) -80% -38.8% -25.7% -25.5% 60.2% 24.2% 32.8% 37%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 2.390 6.260 4.140 4.170 8.310 10.30 13.70 -
Cash Flow per Share - - -1.300 - - - - -
Capex 1 4.23 2.66 3.42 2.23 0.82 8 7.12 14
Capex / Sales 2.72% 1.47% 1.6% 0.68% 0.14% 0.93% 0.59% 0.91%
Announcement Date 2/26/20 2/17/21 2/17/22 2/16/23 2/15/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
263.2 SEK
Average target price
297.7 SEK
Spread / Average Target
+13.10%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BONEX Stock
  4. Financials Bonesupport Holding AB